Marten Schlüter

RFD4-Proteina now runs locally on a MacBook. Introducing BIOS’s Mac port: generate candidate protein binders and screen their predicted structures locally. Built with MLX and custom Metal kernels. • 2.2× faster generation than stock PyTorch-MPS at its default precision • 20 designs generated and screened → 10 ranked candidates in about 12 minutes on GLP-1R (M5 Pro) We believe more researchers should be able to run AI experiments on their own hardware. Test ideas locally, keep your research private, and scale to NVIDIA GPUs when you’re ready. After setup, the workflow runs offline. Watch it run below. ↓

6-12 months ago the large labs started buying bio data this spend is starting to ramp very aggressively. the labs are somewhat indiscriminate buyers with enormous budgets. the therapeutics market has long had buyers of data (large and small pharma) but they've historically been the exact opposite of huge-budget and indiscriminate this shift will distort the bio startup market in a bunch of ways. there will be a lot of short-termist behavior to try to get in front of this capital firehouse. but unlike the AI data labelers (mercor, et al) and the robotics labelers (mecka, et al), the bio startups serving up this data have a chance to emerge from this period with businesses that don't rely on selling data the best bio startups will use these sudden resources the labs are dumping on them to supercharge their novel assay and work towards independently powerful models and eventually directly produce therapies bio is the final frontier and its a very exciting time ahead for bio startups IMO

1/🌐 DAO 2.0: The Distributed Agentic Organization DAO 1.0 showed that coordination could live on‑chain: shared treasuries, automated rules, votes without a CEO. It was groundbreaking—but it had limits. It often drifted toward hidden hierarchies, brittle rules, and shallow participation. DAO 2.0 keeps the “O” (organization) but redefines the first two letters. “Decentralized” becomes Distributed; “Autonomous” becomes Agentic.

Update on NeuroLabs Ignition Sale We want to clarify what happened during the launch and what we’re changing going forward. 1. Based on past launches, we intentionally didn’t communicate a specific finalization time to allow a buffer for the launch to finalize and for us to verify that everything was correct before distributing allocations. However, an outdated message from a previous deployment was still displayed on the finalization page, stating it would happen within 30 minutes. A disruption to our subgraph infrastructure delayed finalization leaving about an hour between the sale ending and TGE. We’re sorry for the wait. 2. We saw concerns about a wallet receiving tokens without participating in the Ignition Sale and selling shortly after. This wallet belonged to a NeuroLabs advisor and had been funded just before the launch. The advisor sold tokens representing 2.15% of the total supply. NeuroLabs AI's tokenomics allocated 14.83% of the total supply to advisors, fully liquid at launch as communicated on the Bio launchpad sale page. We always recommend vesting for team, investor and advisor allocations but accepted the team's request to make the advisor allocation fully liquid for this launch. Going forward, we’ll enforce vesting for all team, investor and advisor allocations to better protect supporters. 3. From our side, we will refund all BioXP spent on the sale to all participants including those who purchased instant BioXP. We believe DeSci should give projects the funding and community support to deliver on their roadmaps beyond the TGE. We're building towards this through early community building and funding on OpenLabs, with permissionless launches and milestone-based funding in development for the Bio launchpad. The goal is to let projects focus on their scientific work, with supporters committed to that longer-term progress. Thank you for your patience and continued trust as we build an ecosystem of tools and communities to move science forward.